Tissue Engineered Solutions for Intracardiac Septal Defects: A La.pdf (602.44 kB)
Tissue Engineered Solutions for Intracardiac Septal Defects: A Large Step Forward in an Unmet Clinical Need.
Version 2 2022-03-28, 15:11
Version 1 2019-11-22, 15:14
report
posted on 2022-03-28, 15:11 authored by Aamir HameedAamir Hameed, Garry DuffyGarry Duffy, Babar Hasan, Saulat Husnain FatimiCongenital heart disease (CHD) is the occurrence of an anomaly in the heart structure during fetal development. The incidence of CHD is estimated to be 8 per 1000 live births in the United States, 6.9 per 1000 live births in Europe and 9.3 per 1000 live births in Asia.1 CHD varies in severity and timing of emergence of symptoms, hence they differ in ways of management.
History
Comments
This is a non-final version of an article published in final form in Hameed A, Duffy GP, Hasan B, Fatimi SH. Tissue Engineered Solutions for Intracardiac Septal Defects: A Large Step Forward in an Unmet Clinical Need. Ann Surg. 2017;265(2):e11-e12Published Citation
Hameed A, Duffy GP, Hasan B, Fatimi SH. Tissue Engineered Solutions for Intracardiac Septal Defects: A Large Step Forward in an Unmet Clinical Need. Ann Surg. 2017;265(2):e11-e12Publication Date
February 2017External DOI
PubMed ID
27811507Department/Unit
- Amber (Advanced Material & Bioengineering Research) Centre
- Anatomy and Regenerative Medicine
- Tissue Engineering Research Group (TERG)
Version
- Accepted Version (Postprint)
